IDH3A and glioblastoma: More recently, a molecular‐based classification (WHO, 2016) for GB was proposed, where isocitrate dehydrogenase wild‐type IDH that accounts for about 90% of cases, frequently corresponds with the clinically defined primary or de novo glioblastoma, and predominates in patients over 55 years old, and GB IDH‐mutant (accounting for 10% of cases), so‐called secondary glioblastoma with a history of prior lower grade diffuse glioma, occurs preferentially in younger patients.2